164 related articles for article (PubMed ID: 38404586)
1. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis.
Marastoni D; Foschi M; Eccher C; Crescenzo F; Mazziotti V; Tamanti A; Bajrami A; Camera V; Ziccardi S; Guandalini M; Bosello F; Anni D; Virla F; Turano E; Romoli M; Mariotti R; Pizzini FB; Bonetti B; Calabrese M
Front Immunol; 2024; 15():1343892. PubMed ID: 38404586
[TBL] [Abstract][Full Text] [Related]
2. CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis.
Marastoni D; Pisani AI; Schiavi G; Mazziotti V; Castellaro M; Tamanti A; Bosello F; Crescenzo F; Ricciardi GK; Montemezzi S; Pizzini FB; Calabrese M
Ther Adv Neurol Disord; 2022; 15():17562864221092124. PubMed ID: 35755969
[TBL] [Abstract][Full Text] [Related]
3. Association of Levels of CSF Osteopontin With Cortical Atrophy and Disability in Early Multiple Sclerosis.
Marastoni D; Turano E; Tamanti A; Colato E; Pisani AI; Scartezzini A; Carotenuto S; Mazziotti V; Camera V; Anni D; Ziccardi S; Guandalini M; Pizzini FB; Virla F; Mariotti R; Magliozzi R; Bonetti B; Steinman L; Calabrese M
Neurol Neuroimmunol Neuroinflamm; 2024 Sep; 11(5):e200265. PubMed ID: 38917380
[TBL] [Abstract][Full Text] [Related]
4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
5. A prospective observational longitudinal study with a two-year follow-up of multiple sclerosis patients on Cladribine.
Al-Hashel J; Ahmed SF; AlMojel M; Alroughani R
Clin Neurol Neurosurg; 2023 Sep; 232():107885. PubMed ID: 37459794
[TBL] [Abstract][Full Text] [Related]
6. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
Aerts S; Khan H; Severijns D; Popescu V; Peeters LM; Van Wijmeersch B
Mult Scler Relat Disord; 2023 Jul; 75():104735. PubMed ID: 37192586
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
11. Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
Magalashvili D; Mandel M; Dreyer-Alster S; Didikin M; Harari G; Flechter S; Achiron A
J Neuroimmunol; 2022 Nov; 372():577966. PubMed ID: 36162338
[TBL] [Abstract][Full Text] [Related]
12. A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis.
Bose G; Rush C; Atkins HL; Freedman MS
Mult Scler Relat Disord; 2021 Jul; 52():102945. PubMed ID: 33901969
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study).
Arena S; Chisari CG; Toscano S; Bucello S; Grimaldi LM; Ragonese P; Realmuto S; Cottone S; Maimone D; Finocchiaro C; Reitano P; Patti F
Curr Neuropharmacol; 2024; 22(7):1271-1283. PubMed ID: 36946484
[TBL] [Abstract][Full Text] [Related]
14. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
16. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Nabizadeh F; Mohamadi M; Rahmani S; Rajabi R; Afrashteh F; Najdaghi S; Mirmosayyeb O
Neurol Sci; 2023 Sep; 44(9):3045-3057. PubMed ID: 37062787
[TBL] [Abstract][Full Text] [Related]
18. Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS.
Håkansson I; Johansson L; Dahle C; Vrethem M; Ernerudh J
Mult Scler Relat Disord; 2019 Nov; 36():101424. PubMed ID: 31586802
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
[TBL] [Abstract][Full Text] [Related]
20. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
